1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Interview: UCB Sees Bimekizumab As Good Long-Term Bet

 
• By Kevin Grogan

UCB immunology chief Emmanuel Caeymaex tells Scrip that despite intense competition, the dual neutralization approach of bimekizumab in inhibiting both interleukin-17A and IL-17F could result in a treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis that may produce faster and more durable clinical improvements than the drugs already on the market.

Tortoise
Slow and steady may win the race

UCB Group's bimekizumab may be well behind the competition in the crowded fields of psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) but to paraphrase Bob Dylan, the slow one now may later be fast if the Belgian drug maker's product candidate continues to hit the high endpoints the company has been setting in clinical studies.

The latest set of strong data on the monoclonal antibody which inhibits both interleukin-17A and IL-17F were presented at the European League Against Rheumatism (EULAR) meeting in Amsterdam last month. In a late-breaking oral presentation of week 12 findings from the Phase IIb BE AGILE study, a greater percentage of patients treated with 16 mg (29.5%), 64 mg (42.6%), 160 mg (46.7%), and 320 mg (45

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

More from Therapy Areas

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.